HER2 Regulates the Mammary Stem/progenitor Cell Population Driving Tumorigenesis and Invasion

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2008 Jul 2

PMID 18591932

Citations 287

Authors

H Korkaya

A Paulson

F Iovino

M S Wicha

Affiliations

Soon will be listed here.

Abstract

The cancer stem cell hypothesis proposes that cancers arise in stem/progenitor cells through disregulation of self-renewal pathways generating tumors, which are driven by a component of 'tumor-initiating cells' retaining stem cell properties. The HER2 gene is amplified in 20-30% of human breast cancers and has been implicated in mammary tumorigenesis as well as in mediating aggressive tumor growth and metastasis. We demonstrate that HER2 overexpression drives mammary carcinogenesis, tumor growth and invasion through its effects on normal and malignant mammary stem cells. HER2 overexpression in normal mammary epithelial cells (NMEC) increases the proportion of stem/progenitor cells as demonstrated by in vitro mammosphere assays and the expression of stem cell marker aldehyde dehydrogenase (ALDH) as well as by generation of hyperplastic lesions in humanized fat pads of NOD (nucleotide-binding oligomerization domain)/SCID (severe combined immunodeficient) mice. Overexpression of HER2 in a series of breast carcinoma cell lines increases the ALDH-expressing 'cancer stem cell' population which displays increased expression of stem cell regulatory genes, increased invasion in vitro and increased tumorigenesis in NOD/SCID mice. The effects of HER2 overexpression on breast cancer stem cells are blocked by trastuzumab in sensitive, but not resistant, cell lines, an effect mediated by the PI3-kinase/Akt pathway. These studies provide support for the cancer stem cell hypothesis by suggesting that the effects of HER2 amplification on carcinogenesis, tumorigenesis and invasion may be due to its effects on normal and malignant mammary stem/progenitor cells. Furthermore, the clinical efficacy of trastuzumab may relate to its ability to target the cancer stem cell population in HER2-amplified tumors.

Citing Articles

Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.

Moffitt L, Karimnia N, Wilson A, Stephens A, Ho G, Bilandzic M Curr Oncol. 2024; 31(12):8023-8038.

PMID: 39727715 PMC: 11674382. DOI: 10.3390/curroncol31120592.

Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.

Engin A Adv Exp Med Biol. 2024; 1460:767-819.

PMID: 39287872 DOI: 10.1007/978-3-031-63657-8_26.

Concise review: breast cancer stems cells and their role in metastases.

Farahani M, Farjadmehr M, Atashi A, Momeni A, Behzadifard M Ann Med Surg (Lond). 2024; 86(9):5266-5275.

PMID: 39238997 PMC: 11374310. DOI: 10.1097/MS9.0000000000002270.

Circulating tumor cells: from new biological insights to clinical practice.

Gu X, Wei S, Lv X Signal Transduct Target Ther. 2024; 9(1):226.

PMID: 39218931 PMC: 11366768. DOI: 10.1038/s41392-024-01938-6.

Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review.

Guo S, Zheng S, Liu M, Wang G Pharmaceutics. 2024; 16(8.

PMID: 39204369 PMC: 11360402. DOI: 10.3390/pharmaceutics16081024.

References

Seidman A, Fornier M, Esteva F, Tan L, Kaptain S, Bach A . Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19(10):2587-95. DOI: 10.1200/JCO.2001.19.10.2587. View

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Allred D, OConnell P, Fuqua S, Osborne C . Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):13-8. DOI: 10.1007/BF00666202. View

Liu S, Dontu G, Mantle I, Patel S, Ahn N, Jackson K . Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006; 66(12):6063-71. PMC: 4386278. DOI: 10.1158/0008-5472.CAN-06-0054. View

Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M . Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004; 6(6):R605-15. PMC: 1064073. DOI: 10.1186/bcr920. View

Wicha M, Liu S, Dontu G . Cancer stem cells: an old idea--a paradigm shift. Cancer Res. 2006; 66(4):1883-90. DOI: 10.1158/0008-5472.CAN-05-3153. View

Stingl J, Eaves C, Kuusk U, Emerman J . Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation. 1998; 63(4):201-13. DOI: 10.1111/j.1432-0436.1998.00201.x. View

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

10.

Finn R, Dering J, Ginther C, Wilson C, Glaspy P, Tchekmedyian N . Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007; 105(3):319-26. DOI: 10.1007/s10549-006-9463-x. View

11.

Kucab J, Lee C, Chen C, Zhu J, Gilks C, Cheang M . Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005; 7(5):R796-807. PMC: 1242152. DOI: 10.1186/bcr1294. View

12.

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

13.

Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M . Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104(18):7564-9. PMC: 1855070. DOI: 10.1073/pnas.0702507104. View

14.

Tanner M, Kapanen A, Junttila T, Raheem O, Grenman S, Elo J . Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2005; 3(12):1585-92. View

15.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

16.

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

17.

Park K, Han S, Kim H, Kim J, Shin E . HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006; 48(6):702-7. DOI: 10.1111/j.1365-2559.2006.02403.x. View

18.

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

19.

Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L . HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003; 22(21):3205-12. DOI: 10.1038/sj.onc.1206394. View

20.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View